We developed a novel, safe, and potent CART19 product that recognizes a membrane-proximal domain of CD19 with fast on- and off-rates and showed significant efficacy and promising safety in patients with relapsed B-cell NHL.
All pts received lymphodepletion with intravenous fludarabine (250 mg/m2) and cyclophosphamide (25 mg/m2) on days -4, -3, and -2. In this first-in-human phase I trial, AT101 was tolerable with limited and manageable toxicities. Notable preliminary efficacy was observed at the RP2D with no evidence of disease relapse after achieving a CR. These results warrant the pursuit of the planned phase II expansion cohort.
Currently, h1218-CART19 (AT101) is in a phase 1 clinical trial in Korea for relapsed and refractory B-cell Non-Hodgkin’s lymphoma patients. Keyword : CD19, CAR T cells, Lymphoma
over 1 year ago
Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
The primary objective is to determine the safety, the maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of AT101 in participants following lymphodepletion with cyclophosphamide and fludarabine (250 mg/m2 and 25 mg/m2). As of January 11, 2023, AT101 has been infused to six patients in cohort 1 and three patients in cohort 2. Detailed results will be presented at the meeting.
over 1 year ago
Clinical • P1 data • CAR T-Cell Therapy • IO biomarker